Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII

✍ Scribed by Liebman, Howard A.; Chediak, Juan; Fink, Kenneth I.; Galvez, Angel G.; Shah, Prabodh C.; Sham, Ronald L.

• Publisher: John Wiley and Sons
• Year: 2000
• Tongue: English
• Weight: 31 KB
• Volume: 63
• Category: Article
• ISSN: 0361-8609
• DOI: 10.1002/(sici)1096-8652(200003)63:3<109::aid-ajh1>3.0.co;2-o

✦ Synopsis

Eight patients with inhibitors to factor VIII (4 hemophilia A and 4 nonhemophilic) were treated with recombinant activated factor VII (rFVIIa) to control severe abdominal bleeding. The recombinant factor was supplied under an open-label, emergency-use program to patients previously unresponsive to one or more alternative therapies. Therapy with rFVIIa was administered for nine separate bleeding events; one patient was treated for two separate bleeding episodes. Patients were treated for an average of 9 days and received a mean total dose of 5.2 mg of rFVIIa for control of bleeding. Treatment was considered successful and hemostasis adequate in 7 of the 9 episodes (78%). Treatment with rFVIIa was partially successful in one other episode. Four patients in this series experienced serious adverse events; all the adverse events were considered unrelated to rFVIIa therapy. The results of this limited series indicate that rFVIIa is an effective means of managing life-threatening abdominal bleeding in individuals with hemophilia or acquired antibodies to factor VIII. Am.